Maxim Group Begins Coverage on CERo Therapeutics (NASDAQ:CERO)

Equities researchers at Maxim Group started coverage on shares of CERo Therapeutics (NASDAQ:CERO) in a report issued on Monday,Benzinga reports. The brokerage set a “buy” rating and a $3.00 price target on the stock. Maxim Group’s price target would indicate a potential upside of 408.47% from the stock’s current price.

A number of other research analysts have also recently commented on the stock. D Boral Capital raised shares of CERo Therapeutics to a “strong-buy” rating in a report on Tuesday, April 22nd. D. Boral Capital initiated coverage on shares of CERo Therapeutics in a report on Tuesday, April 22nd. They set a “buy” rating and a $11.00 target price on the stock.

CERo Therapeutics Stock Performance

CERo Therapeutics stock traded up $0.01 during mid-day trading on Monday, reaching $0.59. The company’s stock had a trading volume of 175,035 shares, compared to its average volume of 783,631. CERo Therapeutics has a twelve month low of $0.53 and a twelve month high of $110.00. The business has a 50 day moving average price of $0.79 and a 200-day moving average price of $5.06.

CERo Therapeutics (NASDAQ:CERO) last posted its quarterly earnings data on Thursday, May 15th. The company reported ($1.59) earnings per share (EPS) for the quarter.

Hedge Funds Weigh In On CERo Therapeutics

Large investors have recently added to or reduced their stakes in the company. Armistice Capital LLC acquired a new position in CERo Therapeutics in the 1st quarter worth about $228,000. Parallel Advisors LLC acquired a new stake in CERo Therapeutics in the first quarter valued at $161,000. ARCH Venture Management LLC increased its position in shares of CERo Therapeutics by 550.4% during the fourth quarter. ARCH Venture Management LLC now owns 9,393,561 shares of the company’s stock worth $564,000 after purchasing an additional 7,949,265 shares in the last quarter. Finally, Avantax Planning Partners Inc. increased its position in CERo Therapeutics by 89.9% in the 4th quarter. Avantax Planning Partners Inc. now owns 2,585,151 shares of the company’s stock valued at $155,000 after acquiring an additional 1,224,021 shares during the period. 29.64% of the stock is currently owned by institutional investors.

CERo Therapeutics Company Profile

CERo Therapeutics Holdings, Inc, an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.